

Featured Protocols

BREAST PROTOCOLS

- **S0230** "A Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer."
- **IBCSG 24-02 SOFT** Suppression of Ovarian Function Trial A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer: Tamoxifen versus Ovarian function suppression + tamoxifen versus Ovarian function suppression + exemestane
- **JMA.17R** A Double Blind Re-Randomization To Letrozole Or Placebo For Women Completing Five Years Of Adjuvant Letrozole In The JMA.17 Study
- **PACCT-1** Program for the Assessment of Clinical Cancer Tests - Trial Assigning Individualized Options for Treatment (**TAILORx** Trial)
- **E5103** A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

GASTRIC SYSTEM PROTOCOLS

- **N0147** A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer
- **E5202** A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin vs 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
- **C80405** A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
- **FERGI017 (AMP 019)** - A Phase 2 Randomized, Double-Blind, Multicenter Trial of Amplimexon® plus Gemcitabine versus Gemcitabine plus Placebo in Patients With Metastatic Chemotherapy Naïve Pancreatic Adenocarcinoma (Stage IV)

LYMPHOMA/LEUKEMIA/HEMATOLOGY PROTOCOLS

- **E5998** A Phase II Study of Initial Treatment with Methotrexate in Large Granular Lymphocytic (LGL) Leukemia
- **CALGB 10501** A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention versus Observation with Later Treatment in the High Risk Genetic Subset with IGV_H Unmutated Disease

LUNG PROTOCOLS

- **E1505** A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) – IIIA Non-Small Cell Lung Cancer (NSCLC)
- **E1504** Phase II Study of C225 (Cetuximab) for the Treatment of Patients with Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features
- **N0723 – MARVEL: Marker Validation of Erlotinib in Lung Cancer - A Phase III Biomarker Validation study of Second-line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) randomized to Pemetrexed Versus Erlotinib**

RENAL PROTOCOLS

- **E2805** A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
- **FERGU018 (CP12-0605):** A Phase II Single Arm Study of IMC-1121B in Patients with Metastatic Renal Cell Carcinoma with Disease Progression on or Intolerance to Therapy with Multi-Targeted Tyrosine Kinase Inhibitors

PROSTATE PROTOCOLS

- **E5805** A Phase II Trial of E7389 (Halichondrin B Analog), In Patients with Metastatic Hormone Refractory Prostate Cancer
- **E3805** CHAARTED – ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer
- **S0421** "Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo For Patients with Advanced Hormone Refractory Prostate Cancer"

MELANOMA PROTOCOLS

- **E1697** Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2b No, T3a-bN0, T4a-b N0, and T1-4, N1a, 2a, 3 (microscopic) Melanoma

GYNECOLOGICAL PROTOCOLS

- **GOG 0209** “A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel/G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer”.